There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthca… This content is
This is mainly useful for risk communication, vaccination advice, and infection-related patient counselling.
ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.